NYSE:JNJ

Johnson & Johnson - JNJ Stock Forecast, Price & News

$166.77

-0.81 (-0.48%)

(As of 08/18/2022 12:00 AM ET)

Add

Compare

Today's Range: $165.93
▼
$168.30
50-Day Range: $165.30
▼
$182.29
52-Week Range: $155.72
▼
$186.69

Volume: 8.30 million shs
Average Volume: 6.37 million shs
Market Capitalization: $438.47 billion

P/E Ratio: 24.28
Dividend Yield: 2.70%
Price Target: $189.89

Johnson & Johnson MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 13.9% Upside
$189.89 Price Target
Short Interest: Healthy
0.45% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.98
Upright™ Environmental Score
News Sentiment: -0.27
Based on 20 Articles This Week
Insider Trading: Selling Shares
$8.44 M Sold Last Quarter
Proj. Earnings Growth: 4.48%
From $10.05 to $10.50 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.82 out of 5 stars

Medical Sector

64th out of 1,119 stocks

Pharmaceutical Preparations Industry

19th out of 549 stocks

2.3

Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $189.89, Johnson & Johnson has a forecasted upside of 13.9% from its current price of $166.77.
Amount of Analyst Coverage
Johnson & Johnson has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the float of Johnson & Johnson has been sold short.
Short Interest Ratio / Days to Cover
Johnson & Johnson has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Johnson & Johnson has recently decreased by 12.71%, indicating that investor sentiment is improving significantly.

4.2

Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 2.70%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 61 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 65.79%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 43.05% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Johnson & Johnson has received a 52.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ustekinumab", "Clinical research services for physical health", "Rivaroxaban", "Daratumumab", "Ibrutinib", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Johnson & Johnson is -1.98.

2.1

News and Social Media Coverage

News Sentiment
Johnson & Johnson has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for Johnson & Johnson this week, compared to 27 articles on an average week.
Search Interest
207 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.
MarketBeat Follows
311 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 87% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,443,160.00 in company stock.
Percentage Held by Insiders
Only 0.35% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
68.78% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 4.48% in the coming year, from $10.05 to $10.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 24.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.40.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 24.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.72.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 3.19. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. UBS Group lowered their price objective on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an "outperform" rating for the company. Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an "overweight" rating in a report on Wednesday, July 13th. Finally, Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an "equal weight" rating in a report on Friday, July 8th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $189.89.

Johnson & Johnson Trading Down 0.5 %

NYSE:JNJ opened at $166.77 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $438.47 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 3.19 and a beta of 0.59. The firm has a fifty day simple moving average of $173.49 and a two-hundred day simple moving average of $174.56. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJ - Get Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts' expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business's quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the company posted $2.48 earnings per share. Analysts expect that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.71%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson's dividend payout ratio (DPR) is presently 65.79%.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company's stock, valued at $2,785,140. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company's stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company's stock, valued at $12,336,803. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the company's stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company's stock, valued at $2,785,140. The disclosure for this sale can be found here. Company insiders own 0.35% of the company's stock.

Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

August 12, 2022 | marketbeat.com

J&J to end sales of baby powder with talc globally next year

Johnson & Johnson is pulling baby powder containing talc worldwide next year after it did the same in the U.S. and Canada amid thousands of lawsuits claiming it had caused cancer

August 10, 2022 | marketbeat.com

Russians buy last goods from H&M, IKEA as stores wind down

Russians are snapping up Western fashion and furniture this week as H&M and IKEA sell off the last of their inventory in Russia

August 19, 2022 | Investing Trends (Ad)

Is the US Military Secretly Under Chinese Control?

Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...

August 9, 2022 | marketbeat.com

Are Medtronic And Intuitive Surgical Poised For Big Growth? (JNJ)

Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.

August 8, 2022 | marketbeat.com

Nonprofits launch $100M plan to support local health workers

A new philanthropic project hopes to invest $100 million in up to 10 countries mostly in Africa by 2030 to support up to 200,000 community health workers

July 31, 2022 | marketbeat.com

Banana Boat recalls scalp sunscreen spray for cancer risk

The maker of Banana Boat sunscreen is recalling a scalp spray because it contains trace amounts of benzene, a chemical which can cause cancer with repeated exposure

July 26, 2022 | marketbeat.com

Drugmaker Teva latest to settle opioid lawsuits nationally

Drugmaker Teva has announced an agreement to settle lawsuits over the allegations that it helped fuel the U.S. opioid epidemic

July 26, 2022 | dividendstocks.com

Is Church & Dwight Co. Inc. (NYSE: CHD) a Buy for Dividend Investors? (JNJ)

August 19, 2022 | Investing Trends (Ad)

Is the US Military Secretly Under Chinese Control?

July 21, 2022 | pricetargets.com

Things Looking Up at Johnson & Johnson?

July 19, 2022 | marketbeat.com

CDC endorses more traditional Novavax COVID shot for adults

Health officials say U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax

July 19, 2022 | marketbeat.com

CDC advisers endorse more traditional Novavax COVID shot

Government advisers say U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax

August 18, 2022 | finance.yahoo.com

Why Is Johnson & Johnson (JNJ) Down 1.8% Since Last Earnings Report?

August 18, 2022 | nasdaq.com

Ex-Dividend Reminder: Energizer Holdings, Johnson & Johnson and Manulife Financial

August 17, 2022 | benzinga.com

If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now

August 17, 2022 | finance.yahoo.com

U.S. to end purchase of COVID-19 vaccines as industry pivots to commercial market

August 16, 2022 | finance.yahoo.com

J&J Unit Tells Appeals Court Only Bankruptcy Can Settle Talc Claims

August 16, 2022 | finance.yahoo.com

Johnson & Johnson Is Out Of The Talc Game — Is It A Buy Now?

August 16, 2022 | forbes.com

What’s Happening With Johnson & Johnson Stock

August 15, 2022 | finance.yahoo.com

10 Important Dividend Increases to Watch in August

August 15, 2022 | benzinga.com

BZ Chart Of The Day: Johnson & Johnson Is Nearing This Key Support Level

August 14, 2022 | bizjournals.com

Johnson & Johnson to stop selling talc-based baby powder

August 13, 2022 | msn.com

Johnson & Johnson will stop selling talc baby powder worldwide

August 12, 2022 | markets.businessinsider.com

Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science

August 12, 2022 | msn.com

Johnson & Johnson Stock: Here’s the Level to Buy, and It’s a Steal

August 12, 2022 | finance.yahoo.com

Johnson & Johnson Stock: Here's the Level to Buy, and It's a Steal

August 12, 2022 | msn.com

Johnson & Johnson will stop selling talcum-based baby powder globally

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Company Calendar

Ex-Dividend for 6/7 Dividend: 5/23/2022
Dividend Payable: 6/07/2022
Last Earnings: 7/19/2022
Today: 8/19/2022
Ex-Dividend for 9/6 Dividend: 8/22/2022
Dividend Payable: 9/06/2022
Next Earnings (Estimated): 10/18/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:JNJ
CUSIP: 47816010
CIK: 200406
Web: www.jnj.com
Phone: (732) 524-0400
Fax: 732-214-0332
Employees: 141,700
Year Founded: 1886

Price Target and Rating

Average Stock Price Forecast: $189.89
High Stock Price Forecast: $205.00
Low Stock Price Forecast: $174.00
Forecasted Upside/Downside: +13.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.87
Trailing P/E Ratio: 24.28
Forward P/E Ratio: 16.59
P/E Growth: 3.19
Net Income: $20.88 billion
Net Margins: 19.21%
Pretax Margin: 21.33%
Return on Equity: 36.14%
Return on Assets: 14.88%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 1.42
Quick Ratio: 1.17

Sales & Book Value

Annual Sales: $93.78 billion
Price / Sales: 4.68
Cash Flow: $12.69 per share
Price / Cash Flow: 13.14
Book Value: $29.04 per share
Price / Book: 5.74

Miscellaneous

Outstanding Shares: 2,629,180,000
Free Float: 2,619,978,000
Market Cap: $438.47 billion
Optionable: Optionable
Beta: 0.59

Social Links

Key Executives

Mr. Alex Gorsky (Age 62)
Exec. Chairman
Comp: $6.18M

Mr. Joaquin Duato (Age 59)
CEO & Director
Comp: $3.53M

Mr. Joseph J. Wolk CPA (Age 55)
Exec. VP & CFO
Comp: $2.58M

Ms. Jennifer L. Taubert (Age 58)
Exec. VP & Worldwide Chairman of Pharmaceuticals
Comp: $2.5M

Mr. Robert J. Decker Jr. (Age 50)
Controller & Chief Accounting Officer

Mr. James Swanson
Exec. VP & Chief Information Officer

Ms. Jessica Moore
VP of Investor Relations

Mr. Michael H. Ullmann (Age 63)
Exec. VP & Gen. Counsel

Mr. Dirk Brinckman
Chief Compliance Officer

Dr. Peter M. Fasolo Ph.D. (Age 59)
Exec. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JNJ Stock - Frequently Asked Questions

Should I buy or sell Johnson & Johnson stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JNJ shares.
View JNJ analyst ratings or view top-rated stocks.
What is Johnson & Johnson's stock price forecast for 2022?: 9 analysts have issued 1 year target prices for Johnson & Johnson's stock. Their JNJ share price forecasts range from $174.00 to $205.00. On average, they expect the company's stock price to reach $189.89 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts price targets for JNJ or view top-rated stocks among Wall Street analysts.
How have JNJ shares performed in 2022?: Johnson & Johnson's stock was trading at $171.07 at the beginning of 2022. Since then, JNJ shares have decreased by 2.5% and is now trading at $166.77.
View the best growth stocks for 2022 here.
Are investors shorting Johnson & Johnson?: Johnson & Johnson saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 11,880,000 shares, a decline of 12.7% from the July 15th total of 13,610,000 shares. Based on an average daily trading volume, of 6,740,000 shares, the short-interest ratio is presently 1.8 days. Approximately 0.5% of the company's stock are short sold.
View Johnson & Johnson's Short Interest.
When is Johnson & Johnson's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 18th 2022.
View our JNJ earnings forecast.
How were Johnson & Johnson's earnings last quarter?: Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings data on Tuesday, July, 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a trailing twelve-month return on equity of 36.14% and a net margin of 19.21%. The firm's revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.48 EPS.
Read the conference call transcript.
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?: Johnson & Johnson declared a quarterly dividend on Monday, July 18th. Investors of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share on Tuesday, September 6th. This represents a $4.52 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend is Monday, August 22nd.
Read our dividend analysis for JNJ.
Is Johnson & Johnson a good dividend stock?: Johnson & Johnson (NYSE:JNJ) pays an annual dividend of $4.52 per share and currently has a dividend yield of 2.70%. The company has been increasing its dividend for 61 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 65.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, JNJ will have a dividend payout ratio of 43.05% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for JNJ.
What guidance has Johnson & Johnson issued on next quarter's earnings?: Johnson & Johnson issued an update on its FY 2022 earnings guidance on Tuesday, August, 2nd. The company provided earnings per share guidance of $10.00-$10.10 for the period, compared to the consensus earnings per share estimate of $10.27. The company issued revenue guidance of $93.30 billion-$94.30 billion, compared to the consensus revenue estimate of $96.04 billion.

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?: 2,535 employees have rated Johnson & Johnson Chief Executive Officer Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among the company's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Johnson & Johnson own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), Procter & Gamble (PG) and AbbVie (ABBV).
What is Johnson & Johnson's stock symbol?: Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
Who are Johnson & Johnson's major shareholders?: Johnson & Johnson's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (5.37%), Northern Trust Corp (1.29%), Price T Rowe Associates Inc. MD (0.94%), Massachusetts Financial Services Co. MA (0.90%), FMR LLC (0.71%) and Deutsche Bank AG (0.58%). Insiders that own company stock include Ashley Mcevoy, Hubert Joly, Kathryn E Wengel, Michael E Sneed, Robert J Decker, Thibaut Mongon, William D Perez and William Hait.
View institutional ownership trends.
How do I buy shares of Johnson & Johnson?: Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Johnson & Johnson's stock price today?: One share of JNJ stock can currently be purchased for approximately $166.77.
How much money does Johnson & Johnson make?: Johnson & Johnson (NYSE:JNJ) has a market capitalization of $438.47 billion and generates $93.78 billion in revenue each year. The company earns $20.88 billion in net income (profit) each year or $6.87 on an earnings per share basis.
How many employees does Johnson & Johnson have?: The company employs 141,700 workers across the globe.
Does Johnson & Johnson have any subsidiaries?: The following companies are subsidiares of Johnson & Johnson: 3Dintegrated ApS, ALZA Corporation, AMO (Hangzhou) Co. Ltd., AMO (Shanghai) Medical Devices Trading Co. Ltd., AMO ASIA LIMITED, AMO Australia Pty Limited, AMO Canada Company, AMO Denmark ApS, AMO Development LLC, AMO France, AMO Germany GmbH, AMO Groningen B.V., AMO International Holdings, AMO Ireland, AMO Ireland Finance Unlimited Company, AMO Italy SRL, AMO Japan K.K., AMO Manufacturing Spain S.L., AMO Manufacturing USA LLC, AMO Netherlands BV, AMO Nominee Holdings LLC, AMO Norway AS, AMO Puerto Rico Manufacturing Inc., AMO Sales and Service Inc., AMO Singapore Pte. Ltd., AMO Spain Holdings LLC, AMO Switzerland GmbH, AMO U.K. Holdings LLC, AMO US Holdings Inc., AMO USA LLC, AMO USA Sales Holdings Inc., AMO United Kingdom Ltd., AMO Uppsala AB, APSIS, AUB Holdings LLC, Abott Medical Optics, Acclarent Inc., Actelion Ltd, Actelion Manufacturing GmbH, Actelion Pharmaceuticals, Actelion Pharmaceuticals Australia Pty. Limited, Actelion Pharmaceuticals Korea Ltd., Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Mexico S.A. De C.V., Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd., Actelion Pharmaceuticals UK Limited, Actelion Pharmaceuticals US Inc., Actelion Registration Limited, Actelion Treasury Unlimited Company, Akros Medical Inc., Albany Street LLC, Alios BioPharma, Alza Land Management Inc., Animas Diabetes Care LLC, Animas LLC, Animas Technologies LLC, AorTx Inc., Aragon Pharmaceuticals, Aragon Pharmaceuticals Inc., Asia Pacific Holdings LLC, Atrionix Inc., Auris Health, Auris Health Inc., Backsvalan 2 Aktiebolag, Backsvalan 6 Handelsbolag, Beijing Dabao Cosmetics Co. Ltd., BeneVir BioPharm Inc., Berna Rhein B.V., BioMedical Enterprises Inc., Biosense Webster (Israel) Ltd., Biosense Webster Inc., C Consumer Products Denmark ApS, CNA Development GmbH, CSATS Inc., Calibra Medical LLC, Campus-Foyer Apotheke GmbH, Carlo Erba OTC S.r.l., Centocor Biologics LLC, Centocor Research & Development Inc., ChromaGenics B.V., Ci:Labo Customer Marketing Co. Ltd., Ci:z Holdings, Ci:z. Labo Co. Ltd., Cilag AG, Cilag GmbH International, Cilag Holding AG, Cilag Holding Treasury Unlimited Company, Cilag-Biotech S.L., CoTherix Inc., Codman & Shurtleff Inc., Coherex Medical Inc., ColBar LifeScience Ltd., Company Store.com Inc., Conor MedSystems, Cordis International Corporation, Cordis de Mexico S.A. de C.V., Corimmun GmbH, DR. CI:LABO COMPANY LIMITED, Darlain Trading S.A., DePuy France, DePuy Hellas SA, DePuy International Limited, DePuy Ireland Unlimited Company, DePuy Mexico S.A. de C.V., DePuy Mitek LLC, DePuy Orthopaedics Inc., DePuy Products Inc., DePuy Spine LLC, DePuy Synthes Gorgan Limited, DePuy Synthes Inc., DePuy Synthes Institute LLC, DePuy Synthes Leto SARL, DePuy Synthes Products Inc., DePuy Synthes Sales Inc., Debs-Vogue Corporation (Proprietary) Limited, Dr. Ci:Labo Co. Ltd., Dutch Holding LLC, ECL7 LLC, EES Holdings de Mexico S. de R.L. de C.V., EES S.A. de C.V., EIT Emerging Implant Technologies GmbH, Ethicon Biosurgery Ireland, Ethicon Endo-Surgery (Europe) GmbH, Ethicon Endo-Surgery Inc., Ethicon Endo-Surgery LLC, Ethicon Holding Sarl, Ethicon Inc., Ethicon Ireland Unlimited Company, Ethicon LLC, Ethicon PR Holdings Unlimited Company, Ethicon Sarl, Ethicon US LLC, Ethicon Women's Health & Urology Sarl, Ethnor (Proprietary) Limited, Ethnor Farmaceutica S.A., Ethnor Guatemala Sociedad Anomina, Ethnor del Istmo S.A., FMS Future Medical System SA, Finsbury (Development) Limited, Finsbury (Instruments) Limited, Finsbury Medical Limited, Finsbury Orthopaedics International Limited, Finsbury Orthopaedics Limited, GH Biotech Holdings Limited, GMED Healthcare BV, Global Investment Participation B.V., Guangzhou Bioseal Biotech Co. Ltd., Hansen Medical Deutschland GmbH, Hansen Medical Inc., Hansen Medical International Inc., Hansen Medical UK Limited, Healthcare Services (Shanghai) Ltd., I.D. Acquisition Corp., Innomedic Gesellschaft für innovative Medizintechnik und Informatik mbH, Innovalens B.V., Innovative Surgical Solutions LLC, J & J Company West Africa Limited, J&J Pension Trustees Limited, J-C Health Care Ltd., J.C. General Services BV, JJ Surgical Vision Spain S.L., JJC Acquisition Company B.V., JJHC LLC, JJSV Belgium BV, JJSV Manufacturing Malaysia SDN. BHD., JJSV Norden AB, JJSV Produtos Oticos Ltda., JNJ Global Business Services s.r.o., JNJ Holding EMEA B.V., JNJ International Investment LLC, JNJ Irish Investments ULC, JOM Pharmaceutical Services Inc., Janssen Alzheimer Immunotherapy (Holding) Limited, Janssen BioPharma Inc., Janssen Biologics (Ireland) Limited, Janssen Biologics B.V., Janssen Biotech Inc., Janssen Cilag C.A., Janssen Cilag Farmaceutica S.A., Janssen Cilag S.p.A., Janssen Cilag SPA, Janssen Development Finance Unlimited Company, Janssen Diagnostics LLC, Janssen Egypt LLC, Janssen Farmaceutica Portugal Lda, Janssen Global Services LLC, Janssen Group Holdings Limited, Janssen Holding GmbH, Janssen Inc., Janssen Irish Finance Company UC, Janssen Korea Ltd., Janssen Oncology Inc., Janssen Ortho LLC, Janssen Pharmaceutica (Proprietary) Limited, Janssen Pharmaceutica NV, Janssen Pharmaceutica S.A., Janssen Pharmaceutical, Janssen Pharmaceutical K.K., Janssen Pharmaceutical Sciences Unlimited Company, Janssen Pharmaceuticals Inc., Janssen Products LP, Janssen R&D Ireland, Janssen Research & Development LLC, Janssen Sciences Ireland Unlimited Company, Janssen Scientific Affairs LLC, Janssen Supply Group LLC, Janssen Vaccines & Prevention B.V., Janssen Vaccines Corp., Janssen de Mexico S. de R.L. de C.V., Janssen-Cilag, Janssen-Cilag (New Zealand) Limited, Janssen-Cilag A/S, Janssen-Cilag AG, Janssen-Cilag AS, Janssen-Cilag Aktiebolag, Janssen-Cilag B.V., Janssen-Cilag Farmaceutica Lda., Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag GmbH, Janssen-Cilag International NV, Janssen-Cilag Kft., Janssen-Cilag Limited, Janssen-Cilag Manufacturing LLC, Janssen-Cilag NV, Janssen-Cilag OY, Janssen-Cilag Pharma GmbH, Janssen-Cilag Pharmaceutical S.A.C.I., Janssen-Cilag Polska Sp. z o.o., Janssen-Cilag Pty Ltd, Janssen-Cilag S.A., Janssen-Cilag S.A., Janssen-Cilag S.A. de C.V., Janssen-Cilag de Mexico S. de R.L. de C.V., Janssen-Cilag s.r.o., Janssen-Pharma S.L., Jevco Holding Inc., Johnson & Johnson, Johnson & Johnson (Angola) Limitada, Johnson & Johnson (China) Investment Ltd., Johnson & Johnson (Egypt) S.A.E., Johnson & Johnson (Hong Kong) Limited, Johnson & Johnson (Ireland) Limited, Johnson & Johnson (Jamaica) Limited, Johnson & Johnson (Kenya) Limited, Johnson & Johnson (Middle East) Inc., Johnson & Johnson (Mozambique) Limitada, Johnson & Johnson (Namibia) (Proprietary) Limited, Johnson & Johnson (New Zealand) Limited, Johnson & Johnson (Philippines) Inc., Johnson & Johnson (Private) Limited, Johnson & Johnson (Thailand) Ltd., Johnson & Johnson (Trinidad) Limited, Johnson & Johnson (Vietnam) Co. Ltd, Johnson & Johnson - Societa' Per Azioni, Johnson & Johnson AB, Johnson & Johnson AG, Johnson & Johnson Belgium Finance Company BV, Johnson & Johnson Bulgaria EOOD, Johnson & Johnson China Ltd., Johnson & Johnson Consumer (Hong Kong) Limited, Johnson & Johnson Consumer (Thailand) Limited, Johnson & Johnson Consumer B.V., Johnson & Johnson Consumer Holdings France, Johnson & Johnson Consumer Inc., Johnson & Johnson Consumer NV, Johnson & Johnson Consumer Saudi Arabia Limited, Johnson & Johnson Consumer Services EAME Ltd., Johnson & Johnson Del Paraguay S.A., Johnson & Johnson Dominicana S.A.S., Johnson & Johnson Enterprise Innovation Inc., Johnson & Johnson European Treasury Company, Johnson & Johnson Finance Corporation, Johnson & Johnson Finance Limited, Johnson & Johnson Financial Services GmbH, Johnson & Johnson Foundation Scotland (NON-PROFIT), Johnson & Johnson Gateway LLC, Johnson & Johnson Gesellschaft m.b.H., Johnson & Johnson GmbH, Johnson & Johnson Guatemala S.A., Johnson & Johnson Health Care Systems Inc., Johnson & Johnson Health and Wellness Solutions Inc., Johnson & Johnson Hellas Commercial and Industrial S.A., Johnson & Johnson Hellas Consumer Products Commercial Societe Anonyme, Johnson & Johnson Hemisferica S.A., Johnson & Johnson Holding GmbH, Johnson & Johnson Holdings K.K., Johnson & Johnson Inc., Johnson & Johnson Industrial Ltda., Johnson & Johnson Innovation - JJDC Inc., Johnson & Johnson Innovation LLC, Johnson & Johnson Innovation Limited, Johnson & Johnson International, Johnson & Johnson International (Singapore) Pte. Ltd., Johnson & Johnson International Financial Services Company, Johnson & Johnson Japan Inc., Johnson & Johnson K.K., Johnson & Johnson Kft., Johnson & Johnson Korea Ltd., Johnson & Johnson Korea Selling & Distribution LLC, Johnson & Johnson LLC, Johnson & Johnson Limitada, Johnson & Johnson Limited, Johnson & Johnson Luxembourg Finance Company Sarl, Johnson & Johnson Management Limited, Johnson & Johnson Medical (China) Ltd., Johnson & Johnson Medical (Proprietary) Ltd, Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Medical (Suzhou) Ltd., Johnson & Johnson Medical B.V., Johnson & Johnson Medical Devices & Diagnostics Group - Latin America L.L.C., Johnson & Johnson Medical GmbH, Johnson & Johnson Medical Korea Ltd., Johnson & Johnson Medical Limited, Johnson & Johnson Medical Mexico S.A. de C.V., Johnson & Johnson Medical NV, Johnson & Johnson Medical Products GmbH, Johnson & Johnson Medical Pty Ltd, Johnson & Johnson Medical S.A., Johnson & Johnson Medical S.C.S., Johnson & Johnson Medical S.p.A., Johnson & Johnson Medical SAS, Johnson & Johnson Medical Saudi Arabia Limited, Johnson & Johnson Medical Servicios Profesionales S. de R.L. de C.V., Johnson & Johnson Medical Taiwan Ltd., Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi, Johnson & Johnson Middle East FZ-LLC, Johnson & Johnson Morocco Societe Anonyme, Johnson & Johnson Nordic AB, Johnson & Johnson Pacific Pty Limited, Johnson & Johnson Pakistan (Private) Limited, Johnson & Johnson Panama S.A., Johnson & Johnson Personal Care (Chile) S.A., Johnson & Johnson Poland Sp. z o.o., Johnson & Johnson Private Limited, Johnson & Johnson Pte. Ltd., Johnson & Johnson Pty. Limited, Johnson & Johnson Research Pty Ltd, Johnson & Johnson Romania S.R.L., Johnson & Johnson S.A., Johnson & Johnson S.A. de C.V., Johnson & Johnson S.E. Inc., Johnson & Johnson S.E. d.o.o., Johnson & Johnson SDN. BHD., Johnson & Johnson Sante Beaute France, Johnson & Johnson Services Inc., Johnson & Johnson Servicios Corporativos S. de R.L. de C.V., Johnson & Johnson Surgical Vision Inc., Johnson & Johnson Surgical Vision India Private Limited, Johnson & Johnson Taiwan Ltd., Johnson & Johnson UK Treasury Company Limited, Johnson & Johnson Ukraine LLC, Johnson & Johnson Urban Renewal Associates, Johnson & Johnson Vision Care (Shanghai) Ltd., Johnson & Johnson Vision Care Inc., Johnson & Johnson Vision Care Ireland Unlimited Company, Johnson & Johnson d.o.o., Johnson & Johnson de Argentina S.A.C. e. I., Johnson & Johnson de Chile Limitada, Johnson & Johnson de Chile S.A., Johnson & Johnson de Colombia S.A., Johnson & Johnson de Costa Rica S.A., Johnson & Johnson de Mexico S.A. de C.V., Johnson & Johnson de Uruguay S.A., Johnson & Johnson de Venezuela S.A., Johnson & Johnson del Ecuador S.A., Johnson & Johnson del Peru S.A., Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda., Johnson & Johnson for Export and Import LLC, Johnson & Johnson s.r.o., Johnson and Johnson (Proprietary) Limited, Johnson and Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi, La Concha Land Investment Corporation, Latam International Investment Company Unlimited Company, LifeScan, MDS Co. Ltd., McNEIL MMP LLC, McNeil AB, McNeil Consumer Pharmaceuticals Co., McNeil Denmark ApS, McNeil Healthcare (Ireland) Limited, McNeil Healthcare (UK) Limited, McNeil Healthcare LLC, McNeil Iberica S.L.U., McNeil LA LLC, McNeil Nutritionals LLC, McNeil Panama LLC, McNeil Products Limited, McNeil Sweden AB, Medical Device Business Services Inc., Medical Devices & Diagnostics Global Services LLC, Medical Devices International LLC, Medical Industrial do Brasil Ltda., Medos International Sarl, Medos Sarl, MegaDyne Medical Products Inc., Menlo Care De Mexico S.A. de C.V., Mentor B.V., Mentor Deutschland GmbH, Mentor Medical Systems B.V., Mentor Partnership Holding Company I LLC, Mentor Texas GP LLC, Mentor Texas L.P., Mentor Worldwide LLC, Micrus Endovascular LLC, Middlesex Assurance Company Limited, Momenta Ireland Limited, Momenta Pharmaceuticals, Momenta Pharmaceuticals Inc., NeoStrata Company Inc., NeoStrata Company Inc., NeoStrata UG (haftungsbeschränkt), Netherlands Holding Company, NeuWave Medical Inc., Neuravi Inc., Neuravi Limited, Novira Therapeutics, Novira Therapeutics LLC, NuVera Medical Inc., OBTECH Medical Sarl, OGX Beauty AU Pty Ltd, OGX Beauty Limited, OMJ Holding GmbH, OMJ Ireland Unlimited Company, OMJ Pharmaceuticals Inc., Obtech Medical Mexico S.A. de C.V., Omrix Biopharmaceuticals Inc., Omrix Biopharmaceuticals Ltd., Omrix Biopharmaceuticals NV, Ortho Biologics LLC, Ortho Biotech Holding LLC, Ortho-McNeil Pharmaceutical LLC, Orthotaxy, Orthotaxy, PMC Holdings G.K., PT Integrated Healthcare Indonesia, PT. Johnson & Johnson Indonesia, Patriot Pharmaceuticals LLC, Peninsula Pharmaceuticals LLC, Penta Pty. Limited, Percivia LLC, Perouse Plastie, Pharmadirect Ltd., Pharmedica Laboratories (Proprietary) Limited, Princeton Laboratories Inc., Productos de Cuidado Personal y de La Salud de Bolivia S.R.L., Proleader S.A., Pulsar Vascular Inc., Regency Urban Renewal Associates, RespiVert Ltd., RoC International, Rutan Realty LLC, SYNTHES Medical Immobilien GmbH, Scios LLC, Sedona Enterprise Co. Ltd., Sedona Singapore International Pte. Ltd., Sedona Thai International Co. Ltd., Serhum S.A. de C.V., Shanghai Elsker For Mother & Baby Co. Ltd, Shanghai Johnson & Johnson Ltd., Shanghai Johnson & Johnson Pharmaceuticals Ltd., Sightbox LLC, Sodiac ESV, Spectrum Vision Limited Liability Company, Spectrum Vision Limited Liability Partnership, Spine Solutions GmbH, SterilMed, SterilMed Inc., Surgical Process Institute Deutschland GmbH, Synthes Costa Rica S.C.R. Limitada, Synthes GmbH, Synthes Holding AG, Synthes Holding Limited, Synthes Inc., Synthes Medical Surgical Equipment & Instruments Trading LLC, Synthes Produktions GmbH, Synthes Proprietary Limited, Synthes S.M.P. S. de R.L. de C.V., Synthes Tuttlingen GmbH, Synthes USA LLC, Synthes USA Products LLC, TARIS Biomedical, TARIS Biomedical LLC, TearScience Inc., The Anspach Effort LLC, The Vision Care Institute LLC, Tibotec LLC, Torax Medical Inc., TriStrata Incorporated, UAB "Johnson & Johnson", Vania Expansion, Verb Surgical, Verb Surgical Inc., Vision Care Finance Unlimited Company, Vogue International, Vogue International LLC, Vogue International Trading Inc., WH4110 Development Company L.L.C., XO1, XO1 Limited, Xian Janssen Pharmaceutical Ltd., Zarbee's Inc., and Zarbee's Naturals.
Read More
When was Johnson & Johnson founded?: Johnson & Johnson was founded in 1886.
How can I contact Johnson & Johnson?: Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The official website for the company is www.jnj.com. The company can be reached via phone at (732) 524-0400 or via fax at 732-214-0332.

This page (NYSE:JNJ) was last updated on 8/19/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Johnson & Johnson - JNJ Stock Forecast, Price & News

Johnson & Johnson MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month